Global S&T Development Trend Analysis Platform of Resources and Environment
Government secures 5 million doses of Moderna vaccine | |
admin | |
2020-11-16 | |
发布年 | 2020 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 ; 资源环境 |
正文(英文) |
Press release
Government secures 5 million doses of Moderna vaccineVaccine could be delivered to the UK from Spring 2021. ![]()
The UK government has completed negotiations with biotech company Moderna to secure access to 5 million doses of its promising vaccine, enough for around 2.5 million people, the Business Secretary announced today (Monday 16 November). If it meets robust standards of safety and effectiveness and approved by the medicines regulator, the vaccine could be delivered to the UK and Europe as early as Spring 2021 with the potential for the government to procure more doses next year. This would follow the first deliveries of the Pfizer/BioNTech and the Oxford University/AstraZenece vaccines which, once final data from their phase 3 clinical trials has been published and if they receive regulatory approval, could be available before the end of the year. The agreement is part of the government’s strategy to develop a diverse portfolio of vaccines, increasing the UK’s chances of securing access to a promising vaccine. Today’s deal means the government has put in place agreements with 7 different developers and has secured 355 million vaccine doses, giving the UK the best possible chance of protecting the public from coronavirus as soon as possible. The news comes as Moderna today publishes initial data showing that its candidate is nearly 95% effective in protecting against COVID-19, with no safety issues identified to date. The safety data is still to be released by Moderna to show whether the vaccine is both safe and effective. Until a vaccine is found to meet robust standards of safety and effectiveness, the public must continue to take necessary actions to keep themselves and their loved ones safe, including following the Hands, Face, Space guidance and other public health advice. Business Secretary Alok Sharma said:
Health Secretary Matt Hancock said:
Moderna is currently conducting phase 3 clinical trials of its vaccine and is using mRNA vaccine technology. The Medicines and Healthcare products Regulatory Agency (MHRA) has started a rolling review of Moderna’s vaccine. MHRA will carefully and scientifically review the safety, quality and effectiveness data once it has all been submitted to determine how it protects people from COVID-19 and the level of protection it provides. The data must include results from the lab and clinical trials; manufacturing and quality controls, product sampling, and testing of the final product. Once they have thoroughly reviewed the data, the MHRA will seek advice from the government’s independent advisory body, the Commission on Human Medicines. They will critically assess the data too before advising the government on the safety, quality and effectiveness of any potential vaccine. The MHRA is globally recognised for requiring the highest standards of safety, quality and effectiveness for any vaccine. Chair of the government’s Vaccine Taskforce Kate Bingham said:
Notes to editorsWe have secured early access to over 355 million vaccines doses through agreements with several separate vaccine developers at various stages of trials, including:
We have invested over £230 million into manufacturing any successful vaccine and an enormous amount of planning and preparation has taken place across government to be able to quickly roll out the vaccine, including ensuring we have adequate provision, transport, PPE and logistical expertise to do so. We are also working at pace to prepare for the delivery of any potential COVID-19 vaccination programme as quickly as possible.
Published 16 November 2020
|
URL | 查看原文 |
来源平台 | Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/302957 |
专题 | 气候变化 资源环境科学 |
推荐引用方式 GB/T 7714 | admin. Government secures 5 million doses of Moderna vaccine. 2020. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论